hypertension, type 2 DM, dyslipidemia) A meta-analysis of 22 trials involving over 17,000 patients determined that 50.2% and 17.5% of patients treated with GLP-1RAs (exenatide, semaglutide & liraglutide) experienced a weight loss of 5% and 10% compared to placebo, and that patients without type 2 diabetes achieved a significantly greater weight loss compared to those with diabetes (Vosoughi et al, 2022)
However, when weight loss occurs too quickly or without regular exercise, the body can lose more than fat
Phase 2 clinical literature (Jastreboff et al., NEJM, 2023
additional concerns include heart rate increases, pancreatitis, and gallbladder disease
They capture a static snapshot but may miss whether use has changed recently or why
In large clinical trials, some people lost around 20 percent of their starting weight with tirzepatide